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Introduction
Sexually transmitted infections (STIs) are a worldwide public 
health challenge, with more than a million new cases occurring 
every day; these are caused by more than 30 different bacteria, 
viruses and parasites.1 Among these, human papillomavirus 
(HPV) and Chlamydia trachomatis (Ct) are the two main sexu-
ally transmitted pathogens.2,3
It is now universally recognized that several oncogenic HPV 
genotypes are the necessary, but not sufficient, cause of cervical 
cancer (CC); most women infected with HPV do not develop 
CC.4,5 Various endogenous and exogenous co-factors, includ-
ing other STIs, that influence the risk of progression from HPV 
infection to invasive CC exist and have been extensively studied.5 
Among these potential co-factors, urogenital Ct infection is of 
particular concern owing to its wide diffusion and heavy public 
health burden. Indeed, genital Ct infection is the most prevalent 
bacterial STI, especially among adolescents and young women.6,7 
Although often asymptomatic, genital Ct infection in women 
may lead to numerous serious and costly complications, such as 
pelvic inflammatory disease, tubal factor infertility, ectopic preg-
nancy and chronic pelvic pain.8,9 In Europe, the prevalence of Ct 
in unscreened asymptomatic women varies significantly among 
countries, ranging from 1.7 to 17%.6 In Italy, no nationwide 
population-based studies on the prevalence of Ct infection have 
yet been performed;10 Ct case notification is not mandatory and 
no screening policy exists.11 A few ad hoc studies conducted in 
Italy11-17 have found Ct prevalence rates ranging from 1.8–10.4% 
among sexually active women, depending on the study popula-
tion and geographic area.
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Infections caused by Chlamydia trachomatis (ct) and human papillomavirus (hPV) are the two main sexually transmit-
ted infections; however, epidemiological data on ct prevalence and ct/hPV co-infection in Italy are scant. This study 
aimed at estimating the prevalence of ct infection and ct/hPV co-infection in young hPV-unvaccinated females with nor-
mal cytology, and placed particular attention on the possible association between ct-DNa positivity and different hPV 
infecting genotypes. Five hundred 66 healthy females aged 16–26 years without cervical lesions, previously assessed 
for hPV infection (hPV-DNa prevalence: 18.2%), were tested for ct-DNa. The overall prevalence of ct was 5.8% (95% cI: 
4.2–8.1), while ct/hPV co-infection was recorded in 2.7% (95% cI: 1.6–4.3) of subjects. compared with hPV-DNa-negative 
females, hPV-DNa positive subjects had significantly (P < 0.001) higher odds of being infected with ct (odds ratio of 4.20, 
95% cI: 2.01–8.71). Both ct and ct/hPV infections were much more prevalent in under 18-year-olds than in older women. 
subjects positive for single high-risk hPV genotypes and various multiple hPV infections had higher odds of being ct-
DNa positive. Our findings confirm that hPV and ct infections are very common among asymptomatic young Italian 
females. This underlines the urgent need for nationwide ct screening programs and reinforcement of sexual health edu-
cation, which would be the most important public health strategies, since no ct vaccines are currently available.
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A specific role of Ct infection in the pathogenesis of cervical 
intraepithelial neoplasia (CIN) and subsequent CC is biologically 
plausible, although as yet there is no univocal and well-established 
evidence on this issue.18,19 Earlier studies have found a significantly 
higher prevalence of Ct-DNA among HPV-positive women than 
HPV-negative ones2,20-22 as well as evidence that Ct is an HPV co-
factor in the etiology of displastic and neoplastic cervical abnor-
malities and CC.23-25 Cervical Ct infection has been clinically 
documented to be associated with cytological atypia and cervical 
metaplasia, thus damaging epithelial integrity, allowing the HPV 
access to the basal epithelium and increasing viral load.19,24 Ct 
may be responsible for increasing the persistence of HPV infec-
tion by affecting viral clearance. Furthermore, the natural history 
of HPV infection may be influenced by Ct-induced chronic cer-
vical inflammation, a reduction in antigen-presenting cells and 
inhibition of cell-mediated immunity. A local deficit of immu-
nity during the reparative phase of the epithelial surface under 
inflammatory conditions may make cervical epithelial cells more 
susceptible to other pathogens.18,19
On the other hand, it has been also suggested that the associa-
tion between Ct and HPV lies only in their shared route of trans-
mission, as both pathogens are markers of sexual risk behaviors.25
Our previous study26 revealed an overall HPV prevalence of 
18.2% among unvaccinated young females with normal cytolog-
ical findings and a particularly high prevalence (10.1%) of high-
risk HPV genotypes, underlining the need to optimize preventive 
measures against STIs among healthy young females. Owing 
to the absence of a national surveillance system and few epide-
miological data available, we conducted a study to estimate the 
prevalence of Ct infection and Ct/HPV co-infection in young 
asymptomatic women without cervical lesions. Our second goal 
was to assess the possible association between Ct-DNA positivity 
and various HPV infecting genotypes.
Results
In our previous study26 566 cervical samples were studied 
to determine the prevalence of different genotypes of HPV in 
16–26-y-old Italian females with normal cytology; the results 
are reported elsewhere.26 Briefly, 103 HPV-DNA-positive and 
463 HPV-DNA-negative samples were identified; in the present 
study, these samples were analyzed for Ct. HPV-DNA-positive 
and -negative groups were comparable in terms of age [19.8 (SD 
2.5) and 19.7 (SD 2.4) years, respectively; t
(564)
 = 0.19, P = 0.85].
Prevalence of Chlamydia trachomatis infection
Overall, 33 out of 566 young women were positive for Ct: a 
prevalence of 5.8% (95% CI: 4.2–8.1%). A higher prevalence of 
Ct infection was found in Genoa [7.7% (95% CI: 4.5–13.0%)] 
than in Milan [6.4% (95% CI: 4.1–9.9%)] and Turin [2.3% 
(95% CI: 0.8–6.6%)]. This difference was not, however, statisti-
cally significant (χ2
(2)
 = 4.04, P = 0.13).
Ct positivity among 16–17-y-olds (n = 27) was at least 3.5-fold 
higher [18.5% (95% CI: 8.2–36.7%)] than in older age-classes 
[18–20 y (n = 376): 5.3% (95% CI: 3.5–8.1%); 21–23 y (n = 
105): 4.8% (95% CI: 2.1–10.7%); 24–26 y (n = 58): 5.2% (95% 
CI: 1.8–14.1%)] with a borderline significance level (Fisher exact 
test: P = 0.075).
Chlamydia trachomatis/HPV co-infection
Ct/HPV co-infection was found in 15 subjects [2.7% (95% 
CI: 1.6–4.3%)]. The prevalence of Ct-DNA positivity was about 
3.7-fold higher among HPV-DNA-positive subjects than among 
HPV-DNA-negative subjects [14.6% (95% CI: 9.0–22.6%) vs. 
3.9% (95% CI: 2.5–6.1%); χ2
(1)
 = 17.49, P < 0.001] with an odds 
ratio (OR) of 4.20 (95% CI: 2.01–8.71). The Ct-DNA preva-
lence was highest among adolescents 16–17 y old and tended to 
be higher among HPV-DNA-positive subjects than HPV-DNA-
negative ones across almost all age-classes, although a statistically 
significant difference was observed only in the 18–20 age-class 
(Fig. 1). Indeed, within the HPV-DNA-positive group, the mean 
Figure 1. Prevalence of Chlamydia trachomatis DNa positivity by age-class and hPV positivity status. *Not significant; **Fisher exact test P = 0.002.
©
20
15
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com human Vaccines & Immunotherapeutics 3
age of females with Ct/HPV co-infection was significantly lower 
(t
(101)
 = 2.05, P = 0.043) than that of Ct-DNA-negative females 
[18.6 (SD 2.1) vs. 20.0 (SD 2.5) years]. The effect size was medium 
(Cohen’s d = 0.61). By contrast, no difference emerged between 
the mean ages of Ct-DNA-positive and Ct-DNA-negative sub-
jects within the HPV-DNA-negative group [19.8 (SD 2.7) and 
19.7 (SD 2.3) years, respectively; t
(461)
 = 0.18, P = 0.86].
Among Ct/HPV co-infected females, 12 out of 15 [80.0% 
(95% CI: 54.8–92.3%)] were positive to at least one high-risk 
(HR) or possible/probable-risk (PR) HPV. The most frequent 
HPV genotype was HPV-16, which was detected in 4 subjects. 
By contrast, low-risk (LR) HPV genotypes were much less fre-
quent [13.3% (95% CI: 3.7–37.9%)] (Table 1).
Logistic regression revealed that females infected with single 
PR [OR = 6.51 (95% CI: 1.60–26.47) P = 0.009], double LR+PR 
[OR = 27.35 (95% CI: 1.47–508.16) P = 0.026] and triple 
HR+HR+LR [OR = 22.90 (95% CI: 1.36–385.80) P = 0.030] 
HPV infections had significantly higher odds of being Ct posi-
tive. Although females infected with HR or HR+HR HPV geno-
types did not reach statistical significance at the P < 0.05 level, 
the effect sizes were large [OR = 2.98 (95% CI: 0.94–9.44) P = 
0.064 and OR = 9.84 (95% CI: 0.98–98.84) P = 0.052, respec-
tively]. Other types of single or multiple HPV infections (LR, 
LR+LR, LR+PR, PR+PR, LR+HR, HR+PR and HR+HR+PR) 
were not statistically significant.
Discussion
This study is among the first to explore some epidemiologi-
cal features of Ct/HPV co-infection among Italian female ado-
lescents and young women with normal cytology. These results 
potentially have several implications for future health policy 
planning. Indeed, knowledge of the prevalence of and risk fac-
tors for these two most common 
STIs is a prerequisite for undertak-
ing effective preventive and control 
measures.
Most of the few studies on Ct 
prevalence conducted in Italy have 
involved women with abnormal 
cytological findings or symptoms 
of STIs.14,15,17 This makes direct 
comparison difficult, since our 
study population was made up of 
asymptomatic female adolescents 
and young women with normal 
cytology. Our Ct prevalence esti-
mate is in line with those of several 
European population-based studies 
among sexually active female ado-
lescents and young women, which 
have reported prevalence rates rang-
ing from 3.6 to 8.0%.27-30 Notably, 
the majority of the women in our 
sample accessed gynecology centers 
seeking the prescription of oral contraceptives (results not shown), 
and the mode of Ct prevalence among European women seeking 
contraception is estimated, as in our study, to be about 6%.6 In a 
recently performed meta-analysis, Ct prevalence in high-income 
countries was estimated to be 4.32% among sexually active 
females aged ≤ 26 y.10 By contrast, in a study conducted in Brescia 
(Italy),12 an unexpectedly low Ct prevalence of 1.9% among sexu-
ally experienced healthy female students was documented. This 
inconsistency with our results could be explained in several ways. 
First, it could be due to the difference in study locations, as Ct 
prevalence varies geographically.6 Indeed, we observed a 3.3-fold 
difference in Ct prevalence between Genoa and Turin; thus, the 
estimate from Brescia is almost consistent with the figure we 
recorded in Turin. Second, our study population also included 
female adolescents aged 16–17 y—the age-class which displayed 
the highest Ct prevalence—while the study by Matteelli et al.12 
enrolled only women aged ³18 y. Finally, the difference could 
be ascribed to the recruitment process; the participants in our 
study were enrolled at the gynecology centers of local health units 
(LHUs), while those in Brescia were recruited at high schools.
Our results confirm previous findings of significantly higher Ct 
prevalence among HPV-positive than HPV-negative women.2,20-
22 A systematic review by Silva et al.19 reported Ct-DNA positivity 
prevalence rates of 4–59% among HPV-positive women living in 
different continents; however, when only estimates from Europe 
were considered, this range narrowed to 10–24%. By contrast, 
Ct-DNA positivity among HPV-negative controls reported 
in their paper was substantially lower, rarely exceeding 10%.19 
Research conducted in Italy by Verteramo et al.17 found a Ct fre-
quency of 13.9% among HPV-positive women, as against 5.4% 
among HPV-negative women; these figures are similarly to our 
estimates. However, in a recent paper by Sammarco et al.,13 Ct 
prevalence in HPV-positive women aged 18–63 y without cervi-
cal lesions was estimated to be as low as 6.3%, which is about half 
Table 1. hPV genotypes found among Chlamydia trachomatis DNa-positive subjects, by urban area and age
Residence Age, years
HR HPV 
genotypes
PR HPV 
genotypes
LR HPV 
genotypes
Untypeable 
HPV (NT)
Genoa 16 – – 11 –
Genoa 17 – 67 – –
Genoa 17 – – 87 –
Genoa 17 – 53 – –
Milan 18 52, 58 66 – –
Milan 18 52 – – –
Milan 18 16 – – –
Milan 18 16, 31 – 40 –
Genoa 18 52 – 61 –
Genoa 18 16 – – –
Milan 19 – 73 – –
Turin 19 16, 58 – 61 –
Turin 20 – – – +
Genoa 22 56 – – –
Milan 24 – 66 54 –
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our figure. Again, the difference observed is very probably due to 
the different age profiles of the study populations.
In our study, both Ct-DNA positivity and HPV/Ct co-infec-
tion displayed age disparities, with a much higher prevalence 
among female adolescents under 18 y old; this is in line with the 
well-established evidence that sexually active adolescent females 
are at higher risk of genital Ct infection than older females.31-34 
Indeed, a meta-analysis by Adams et al.35 revealed that the OR 
of being infected with Ct diminished as age increased. Similarly, 
in a large Italian study,16 female adolescents between 15 and 19 
y had the highest Ct prevalence. Another interesting finding 
concerns the association between the lower age of Ct-infected 
subjects than of Ct-DNA-negative ones within the HPV-DNA-
positive group. That patients with concurrent STIs tend to be 
younger has already been suggested by Griffiths et al.36 However, 
Tamim et al.2 did not find any association between age and Ct 
positivity within the HPV-positive group; this was probably the 
result of the lower sample size in their study. By contrast, our 
finding not only reached statistical significance at α level <0.05, 
this between-group age difference of about 1.5 y is also of prac-
tical significance, as demonstrated by the effect size. This sug-
gests the need to strengthen health education, counseling and 
other preventive measures before sexual debut, which has been 
estimated to be around 15 y old.37
An association between Ct and HR HPV genotypes has been 
described previously.19 As expected, the most frequently detected 
HPV genotype among our subjects co-infected with Ct was HPV-
16, and most of co-infections involved at least one HPV genotype 
belonging to groups 1, 2A or 2B of the International Agency for 
Research on Cancer (IARC).38 This finding is not surprising, 
since HPV-16 is the most prevalent genotype in Italy39,40 and in 
many other geographical areas.41 Analogous results have been 
reported by Tamim et al.2 who found HPV-16 to be the most 
frequent genotype in HPV/Ct co-infections. The results of our 
regression analysis showed that women infected with single HR/
PR and different combinations of multiple HPV genotypes with 
at least one HR/PR HPV type had significantly higher odds of 
being co-infected with Ct. This finding is of particular impor-
tance for the primary prevention of CC, since concurrent Ct 
infection has been found to be associated with the persistence 
of HR and multiple HPV genotypes in female adolescents.42 In 
turn, the persistence of HR HPV genotypes among cytologically 
normal women leads to a greatly increased risk of CC.43
It is noteworthy that the findings from our cross-sectional 
study did not allow us to determine which infection, HPV or 
Ct, occurred first. However, our main aim was to determine Ct 
and Ct/HPV infection prevalence among HPV-unvaccinated 
young women, and not to establish any causality. Another limita-
tion of this explorative study is its relatively small sample size; 
this explains the large confidence intervals of the coefficients 
obtained from the logistic regression model. At the same time, 
the sample size was sufficient to identify large effect sizes associ-
ated with some specific HPV genotypes and their combinations.
In conclusion, the results of the present study highlight the 
fact that genital Ct infection is common among young HPV-
unvaccinated females with normal cytology in three large 
metropolitan areas in northern Italy. Approximately one fifth 
of asymptomatic females in our sample tested positive for HPV 
and/or Ct, suggesting that the epidemiological features of STIs 
in Italy may fit into the “silent epidemic” context.44 Indeed, the 
study population referred no symptoms of the STIs confirmed by 
subsequent gynecological examination. This observation stresses 
the need for nationwide Ct screening programs, which would be 
the most important viable and potentially cost-effective public 
health strategy in the absence of a Ct vaccine.45 With regard to Ct 
vaccines, several candidates are under preclinical development, 
and a safe and effective vaccine is seen as the ultimate goal in 
the control of Ct;45 indeed, mathematical modeling has shown 
that fully protective vaccination would eliminate Ct epidemics in 
about two decades.46
Finally, in Italy public health policies towards these two most 
common STIs display several critical features, including far from 
optimal HPV vaccination47 and cervical screening coverage,48 
and inadequate Ct case notification and Ct screening;11 these 
issues must be addressed as public health priorities.
Materials and Methods
The study was approved by the Ethics Committee of the LHU 
in Genoa, Italy.
Study population
In this study, cervical samples which had already been tested 
for HPV-DNA were examined to detect Ct-DNA.16 Briefly, sub-
jects aged 16–26 y were recruited in three cities in northern Italy 
(Turin, Milan and Genoa). All consecutive eligible young women 
who spontaneously accessed the gynecology centers of LHUs for 
medical consultations from 1st January to 30th June 2010 were 
enrolled.
All participants gave written informed consent. The inclusion 
criteria were: being sexually active, not being pregnant, not being 
symptomatic for any STI, not having been vaccinated against 
HPV, and no previous history of cervical abnormalities. All par-
ticipants underwent a Pap smear and only those with normal 
cytology were studied.
Sample collection
Cervical smear samples were collected by means of a spatula, 
immersed and rinsed in a vial containing 20 ml of PreservCyt® 
solution (ThinPrep Pap Test, Hologic; cod.70136-001) and 
stored until processing at room temperature. The samples were 
analyzed in the molecular laboratory of the Department of 
Biomedical Sciences for Health of Milan University.
PreservCyt® solution (10 ml for each sample) containing cer-
vical cells was centrifuged at 3800 g for 10 min at room tempera-
ture. After centrifugation, pellets were resuspended in 1 ml of 
phosphate buffered saline, transferred into a new 1.5 ml collec-
tion test-tube and stored at -20 °C until nucleic acid extraction.
Nucleic acid extraction
The NucliSENS® EasyMAG® (bioMérieux; cod. 200111) 
commercial kit was used for DNA extraction following the man-
ufacturer’s instructions. A Thermo Scientific NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific Inc) was used to 
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ascertain the concentration and purity of the DNA extracted, 
while DNA integrity was evaluated by amplification of a 268 
base pair (bp) fragment in the ubiquitous β-globin gene by using 
the primer pair PCO
4
 and GH
20
.49
HPV DNA detection and Restriction Fragment Length 
Polymorphism genotype analysis
HPV DNA was detected by PCR amplification of a 450-bp 
segment of ORF L1, as previously described.50,51 Briefly, 50–100 
ng of DNA was added to the PCR master mix containing an 
equimolar mixture of each primer ELSI-f and ELSI-r (30 pmol/
μl), and the GoTaq® DNA Polymerase (Promega; cod. M3175). 
Amplification reaction conditions were 5 min denaturation at 94 
°C, followed by 40 cycles of amplification consisting of a dena-
turation step at 94 °C for 30 s, an annealing step at 55 °C for 30 
s and an elongation step at 72 °C for 30 s. The last cycle was fol-
lowed by a 7 min elongation step at 72 °C.
Positive (DNA extracted from HPV 16-positive cells, Caski) 
and negative (water) control samples were inserted in each PCR 
run. The amplified products were revealed by electrophoresis 
analysis of 2% agarose gels containing ethidium bromide. The 
amplification product bands were then compared with molecular 
weight standards (DNA Molecular Weight, Marker 100, Sigma-
Aldrich; cod. G8291).
All amplified fragments were genotyped by means of 
Restriction Fragment Length Polymorphism (RFLP) capable of 
identifying all genotypes, including HR, PR and LR genotypes, 
according to the latest IARC classification.38
One μg of each amplified product was added to three differ-
ent digestion solutions, each containing 1U of either RsaI, DdeI 
or HaeIII (New England BioLabs; cod. R0167L; cod. R0175L; 
cod. R0108L) restriction enzymes diluted in their respective buf-
fers for 1 h at 37 °C. The digestion products were determined 
following separation in 3% agarose gels, and restriction patterns 
were compared with appropriate standards (DNA Molecular 
Weight, Marker 100+20, Sigma-Aldrich; cod. D7808). The 
pattern of fragments generated by the three restriction enzymes 
allowed genotypes to be identified.52,53
Each sample that displayed a complex/undetermined pattern 
on RFLP was retested. Samples that could not be assigned to 
an HPV genotype after 2 consecutive analyses were defined as 
“untypeable” (NT).
Chlamydia trachomatis
DNA detection
A nested PCR assay targeting a 150 bp segment of the cryptic 
plasmid of Ct was performed. The two primer pairs of primers 
used in the two PCR runs have previously been described by Jalal 
et al.54 Briefly, 50–100 ng of DNA was added to the PCR master 
mix containing an equimolar mixture of each primer (25 pmol) 
and the GoTaq® DNA Polymerase (Promega; cod. M3175). 
Each run included positive controls (DNA extracted from 
human Ct-positive cervical cells) and negative (water) controls. 
Amplification reaction conditions were 5 min of denaturation 
at 94 °C, followed by 30 cycles (first run) and 25 cycles (second 
run). Each cycle consisted of a denaturation step at 94 °C for 
30 s, an annealing step at 50 °C for 30 s, and an elongation step 
at 72 °C for 30 s. The last cycle was followed by a 7 min elon-
gation step at 72 °C. The amplification products were revealed 
by means of electrophoresis analysis of 2% agarose gels contain-
ing ethidium bromide. Amplified product bands were compared 
with molecular weight standards (DNA Molecular Weight, 
Marker 100, Sigma-Aldrich; cod. G8291).
Statistical analysis
The normally distributed continuous variable “age” was 
expressed as mean and standard deviation (SD) and the two-
sample Student’s t test was used to evaluate between-group dif-
ference in age. As the measure of effect size for the t test, Cohen’s 
d was used. Cohen’s d was interpreted as follows: small (d = 0.2), 
medium (d = 0.5) and large (d = 0.8).55 The prevalence of Ct-DNA 
positivity with 95% confidence intervals (CIs), estimated by 
using Wilson’s score, was calculated both for the overall study 
population and by age-class (broken down into 4 age-classes: 
16–17, 18–20, 21–23, and 24–26 y old on the basis of previous 
research26), province of residence and HPV-DNA positivity sta-
tus. To compare frequency distributions, Fisher’s exact test was 
performed if ³20% of expected frequencies were <5; otherwise, 
the chi-square test was applied. To detect a possible association 
between Ct-DNA positivity (dependent variable) and specific 
HPV genotypes (dummy-coded independent variable with the 
reference category of HPV-DNA-negative observations), a multi-
variable logistic regression analysis was performed; all ORs were 
adjusted for age and province of residence. Categories of single 
HPV infections were dummied in accordance with the latest 
IARC classification38 and presented as HR, PR and LR geno-
types. Double and triple infections were dummied on the basis of 
our previously reported26 different HPV combinations: LR+LR, 
LR+PR, PR+PR, LR+HR, HR+PR, HR+HR, HR+HR+LR and 
HR+HR+PR. A two-sided p-value < 0.05 was considered statisti-
cally significant. All analyses were performed by means of the R 
stats package, version 3.0.1.56
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